Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 0 · 0%Moderate 0 · 0%High 1 · 50%

Mirtazapine vs tricyclic antidepressants (TCAs)

Acceptability ‐ total dropouts · adults with cancer and depression

It is very uncertain whether mirtazapine changes dropouts due to any cause (acceptability) compared with tricyclic antidepressants (TCA) (very low certainty).

1 finding from 1 review

Antidepressants for the treatment of depression in people with cancer 2023 · Cochrane Headline outcomes only
RR 0.65 [0.2, 2.15]
1 study · 33 participants
Very low

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine (30 mg/d) vs augmentation of current antidepressant (various) with placebo

Leaving the study early · treatment‐resistant depression in adults

Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in dropouts compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).

1 finding from 1 review

Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
RR 0.5 [0.15, 1.62]
1 study · 480 participants
High